| (Values in U.S. Thousands) | Jun, 2023 | Mar, 2023 | Dec, 2022 | Sep, 2022 | Jun, 2022 |
| Sales | 64,650 | 66,310 | 60,700 | 65,900 | 74,140 |
| Sales Growth | -2.50% | +9.24% | -7.89% | -11.11% | -36.01% |
| Net Income | 5,160 | 5,750 | 8,170 | -7,130 | -9,450 |
| Net Income Growth | -10.26% | -29.62% | +214.59% | +24.55% | -121.45% |
Eagle Pharmaceuticals Inc (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.
Fiscal Year End Date: 12/31